〔Abstract〕 Objective To investigate the role of CCL23-CCR1 axis in progression of epithelial ovarian cancer. Methods Serum level of 441 kinds of chemokines was detected using RioBiotech antibody array in 6 patients with epithelial ovarian cancer and 4 normal adult females. Candidate biomarker was identified by SPSS analysis. We identified CCL23 as the differentially expressed protein. Serum levels of CCL23 in 22 normal adult females and 36 epithelial ovarian cancer patients were detected by ELISA. qRT-PCR was used to detect the expression of CCL23 mRNA in 6 normal adult ovarian tissues and 6 epithelial ovarian cancer tissues. Immunohistochemistry was used to detect the expression of CCR1 in situ lesions of 20 cases of Stage Ⅰ, 20 cases of Stage Ⅱ, 40 cases of Stage Ⅲ and 20 cases of Stage Ⅳ epithelial ovarian cancer. Results The concentrations of 441 cytokines were detected using antibody array, and CCL23 concentration was(21 924.20±2 647.89)pg/ml in normal control group while(44 902.00±2 064.03)pg/ml in patients with epithelial ovarian cancer(t=-2.693,P=0.041), the difference was statistically significant. Serum levels of CCL23 were(1 157.80±457.40)pg/ml in 22 normal adult women while(1 654.90±849.00) pg/ml in 36 cases of epithelial ovarian cancer patients(t=-0.244 3,P=0.018 8), the difference was statistically significant. The expression of CCL23 mRNA in epithelial ovarian cancer tissue was significantly higher than that in normal ovarian tissue(t=-7.515,P=0.006). The expression of CCR1 in situ lesions of epithelial ovarian cancer using immunohistochemistry demonstrated that ovarian surface epithelial(OSE) presented negative expression of CCR1. In contrast, the expression of CCR1 in 60 cases of stage Ⅲ/Ⅳ was higher than 40 cases of stage Ⅰ/Ⅱ. Conclusion CCL23-CCR1 axis may play a role in the progression of epithelial ovarian cancer.